Skip to content
24/7 Support
Save up to 80%
Fast & Discrete Delivery
Empagliflozin

Empagliflozin

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Active ingredient Empagliflozin

Free delivery on orders from AED 796.00, free express delivery from AED 1,194.00

Empagliflozin is an oral medicine for adults with type 2 diabetes and certain heart or kidney conditions. It helps lower blood glucose by causing the kidneys to remove more glucose through urine, while offering cardiovascular and renal benefits in suitable patients.

Description

Empagliflozin is an oral antidiabetic medicine in the SGLT2 inhibitor class, prescribed for adults with type 2 diabetes and selected cardiovascular or kidney conditions. It lowers glucose by increasing urinary glucose excretion and can provide heart and kidney protection in appropriate patients.

Composition

Empagliflozin is an oral antidiabetic medicine in the SGLT2 inhibitor class. It is prescribed for adults with type 2 diabetes and selected heart failure or chronic kidney disease conditions. The medicine lowers blood glucose by increasing the excretion of glucose through the urine and may provide cardiovascular and renal benefits in appropriate patients. Exact product details are stated in the approved local information.

Dosage and usage

Empagliflozin tablets are taken by mouth once daily when prescribed for standard adult treatment. The precise strength and dose depend on the approved product information, kidney function, treatment indication, and the clinician’s plan.

Practical administration points include:

  • Take the tablet at the same time each day.
  • Swallow it with water.
  • It may generally be taken with or without food.
  • Maintain regular fluid intake unless a clinician has prescribed fluid restriction.
  • Do not take two doses together after a missed dose.
  • Ask for specific instructions before surgery, prolonged fasting, or severe illness.
  • Continue prescribed diabetes monitoring, including blood-glucose checks when advised.

Empagliflozin can increase urine volume. Taking it late at night may disturb sleep because of urination, so morning administration is often more convenient when compatible with the prescribed regimen.

Do not stop insulin abruptly if insulin is also prescribed. Sudden insulin reduction while taking an SGLT2 inhibitor can increase ketoacidosis risk, including during periods when glucose readings do not appear severely elevated.

Keep a record of recurring genital irritation, urinary discomfort, dizziness, or sudden weight change. These details help a clinician distinguish an isolated symptom from a pattern related to treatment or fluid balance.

How it works

The kidneys filter glucose from the blood and normally return most of it to the circulation through SGLT2 transporters in the proximal tubules. Empagliflozin blocks this transporter, reducing glucose reabsorption and increasing the amount of glucose passed in urine. The result is lower circulating glucose without directly stimulating pancreatic insulin release. [1]

This mechanism explains two practical features. The medicine can work even when insulin production is reduced, and it may cause more frequent urination, especially during the first weeks or when fluid intake is high.

Indications

Empagliflozin is used to improve glycaemic control in adults with type 2 diabetes mellitus alongside dietary measures and physical activity. It is also used in specific patients with heart failure or chronic kidney disease, where SGLT2 inhibition may reduce the risk of hospitalisation and disease progression. The exact indication depends on the approved local product information and the patient’s clinical profile.

The European Medicines Agency recognises empagliflozin-based treatment for type 2 diabetes and has evaluated its cardiovascular and renal benefits in defined patient groups. MOHAP regulates medicines and prescribing practice in the United Arab Emirates. [2]

Clinical setting Main therapeutic goal
Type 2 diabetes mellitus Reduce blood glucose and improve glycaemic control
Heart failure in suitable adults Lower the risk of heart-failure hospitalisation and related cardiovascular events
Chronic kidney disease in suitable adults Slow kidney-function decline and reduce kidney or cardiovascular complications

Empagliflozin does not treat type 1 diabetes. Its use in type 1 diabetes may increase the risk of diabetic ketoacidosis, including cases where blood glucose is not extremely high. It is also unsuitable for treating diabetic ketoacidosis itself.

Doctors often review kidney function before starting treatment and during follow-up. Reduced kidney function can alter the glucose-lowering response and may change whether treatment is appropriate.

Tell the prescribing clinician about planned surgery, prolonged fasting, vomiting, diarrhoea, or a severe infection. Temporary interruption may be needed during these situations to reduce dehydration and ketoacidosis risk.

Comparison

Empagliflozin differs from metformin, sulfonylureas, insulin, and incretin-based treatments because its primary action takes place in the kidney rather than directly in the pancreas or liver. This difference affects both benefits and adverse effects.

Treatment approach Main mechanism Main clinical limitation
Empagliflozin Blocks renal SGLT2 and increases urinary glucose excretion Dehydration, genital infections, and ketoacidosis risk in susceptible situations
Metformin Reduces hepatic glucose production and improves insulin sensitivity Gastrointestinal intolerance and restrictions in advanced kidney impairment
DPP-4 inhibitor plus metformin Enhances glucose-dependent incretin activity alongside reduced hepatic glucose production Usually more modest glucose lowering and limited heart or kidney benefits compared with SGLT2 therapy

A DPP-4 inhibitor and metformin combination may suit a person who needs additional glucose control with a low risk of hypoglycaemia and no need for a diuretic effect. Empagliflozin may be favoured when heart failure, chronic kidney disease, or cardiovascular risk makes its additional organ benefits clinically relevant.

Insulin remains essential for type 1 diabetes and may be needed in advanced type 2 diabetes when pancreatic insulin production is insufficient. Empagliflozin cannot replace insulin in those circumstances.

The choice is not based on blood glucose alone. The American Diabetes Association and international diabetes guidance place increasing emphasis on cardiovascular disease, heart failure, kidney disease, weight, hypoglycaemia risk, tolerability, and patient preference. [3]

Contraindications

Empagliflozin is not suitable for everyone. The prescribing clinician considers kidney function, diabetes type, hydration status, previous ketoacidosis, and concurrent medicines before treatment.

  • Type 1 diabetes unless a specialist has given a specific, closely monitored plan.
  • Active diabetic ketoacidosis.
  • A previous serious reaction to empagliflozin or an excipient in the prescribed tablet.
  • Severe dehydration or inability to maintain fluid intake.
  • Severe kidney impairment that makes treatment unsuitable.
  • Prolonged fasting or major surgery without an agreed medication plan.

Important interactions and cautions include:

  • Insulin and sulfonylureas may increase hypoglycaemia risk.
  • Diuretics may increase dehydration, dizziness, and low blood pressure.
  • Lithium requires careful monitoring because changes in kidney handling and fluid balance may affect lithium concentrations.
  • Alcohol excess, ketogenic dieting, prolonged fasting, infection, and abrupt insulin reduction may increase ketoacidosis risk.
  • Pregnancy and breastfeeding require an individual assessment because treatment may not be suitable.
  • Recurrent genital infections may require a review of treatment tolerability.

[4] Empagliflozin addresses one part of that strategy; blood-pressure control, lipid management, nutrition, physical activity, and routine monitoring remain separate clinical priorities.

When this is not for you

This medicine may not be suitable for you if you have type 1 diabetes, active diabetic ketoacidosis, severe dehydration, or severely reduced kidney function. Tell your clinician if you have had a serious reaction to empagliflozin, cannot keep fluids down, or are preparing for major surgery or prolonged fasting. You should also discuss insulin, sulfonylureas, diuretics, lithium, pregnancy, breastfeeding, recurrent genital infections, alcohol excess, and ketogenic dieting before treatment.

Side effects

Many adults tolerate empagliflozin without major difficulty, but its renal mechanism creates predictable effects. Increased urination, thirst, dehydration, genital fungal infection, and urinary tract infection are among the main concerns described in regulatory information.

Common or clinically relevant effects include:

  • Increased urination or urinary volume.
  • Thirst and dry mouth.
  • Dizziness from fluid depletion.
  • Genital itching, irritation, or fungal infection.
  • Urinary tract symptoms.
  • Constipation or gastrointestinal discomfort.
  • Reduced blood pressure, especially with diuretics or in older adults.

Hypoglycaemia is less common when empagliflozin is used alone because the medicine does not directly force insulin release. The risk rises when it is combined with insulin or medicines that stimulate insulin secretion.

Urgent medical assessment is required for nausea, vomiting, abdominal pain, unusual tiredness, rapid breathing, confusion, or a sweet-smelling breath. These may indicate diabetic ketoacidosis. Seek immediate care for severe genital pain, swelling, fever, or rapidly worsening tissue inflammation.

One easily missed detail is that ketoacidosis can occur with only moderately elevated glucose. A normal-looking glucose reading does not rule it out when compatible symptoms are present.

Another practical issue involves low blood pressure. People taking loop or thiazide diuretics may experience more fluid loss after starting an SGLT2 inhibitor, especially during hot weather or reduced food intake.

Common mistakes

Several avoidable errors reduce the safety and usefulness of empagliflozin treatment:

  • Stopping insulin because glucose readings improve.
  • Continuing the medicine through repeated vomiting or severe diarrhoea without seeking instructions.
  • Ignoring genital itching or urinary burning.
  • Following a strict ketogenic diet without discussing ketoacidosis risk.
  • Taking extra tablets after a missed dose.
  • Assuming normal blood glucose excludes ketoacidosis.
  • Failing to mention diuretics, lithium, or frequent fasting.
  • Treating excessive thirst as an expected effect rather than a possible sign of dehydration.
Before a planned operation, ask for a written stop-and-restart plan. The timing depends on the procedure, kidney function, food intake, and local clinical instructions, so improvising on the day is unsafe.

What doctors say

In clinical practice, doctors usually set expectations around gradual improvement rather than an immediate change in symptoms. Empagliflozin lowers glucose through the kidneys, while cardiovascular and renal benefits are assessed over longer follow-up periods.

A physician will commonly review:

  • Kidney function before treatment and at intervals.
  • Blood pressure and symptoms of fluid depletion.
  • Genital or urinary infections.
  • Concurrent insulin, sulfonylurea, and diuretic therapy.
  • Sick-day and surgery instructions.
  • Glycated haemoglobin and other diabetes markers.

The medicine can be a strong option when type 2 diabetes coexists with heart failure or chronic kidney disease. Its limitations are equally clear: it is not a substitute for insulin in insulin-deficient states, and its diuretic-like effects can become troublesome in people who are frail, dehydrated, or taking several blood-pressure medicines.

Frequently asked questions

Does Empagliflozin lower blood glucose?

Empagliflozin lowers blood glucose by reducing renal glucose reabsorption and increasing glucose loss in urine. The effect is independent of direct insulin stimulation, although insulin treatment may still be necessary for some people. Regulatory evaluations by the EMA in 2024 support its use in appropriate adults with type 2 diabetes. [5] The glucose-lowering response varies with kidney function and the prescribed regimen. It should be assessed alongside the person's individual diabetes plan.

Can Empagliflozin be used for heart failure?

Empagliflozin may be prescribed for selected adults with heart failure, including some patients without diabetes. Clinical trials have shown reductions in heart-failure hospitalisation and related outcomes in defined populations. The FDA's 2023 label and the EMA's 2024 product information define indications according to the patient's heart-failure type, kidney function, and treatment plan.

Does Empagliflozin cause hypoglycaemia?

Empagliflozin alone has a relatively low tendency to cause hypoglycaemia because it does not directly increase insulin secretion. The risk becomes greater when it is combined with insulin or a sulfonylurea. NICE guidance from 2022 supports reviewing the doses of accompanying glucose-lowering medicines when hypoglycaemia occurs.

What happens if a dose is missed?

Take the missed tablet when remembered if the next scheduled dose is not close. Skip it when the next dose is due soon, then return to the usual schedule. The WHO's 2023 diabetes framework supports avoiding double dosing and maintaining a consistent long-term treatment routine.

Can Empagliflozin be taken during vomiting or diarrhoea?

Vomiting and diarrhoea can cause dehydration and may increase the risk of ketoacidosis during SGLT2 inhibitor treatment. Contact the treating service promptly for sick-day instructions, especially if food and fluids cannot be maintained. MOHAP's 2023 patient-care guidance commonly emphasises medication review during acute illness, though the individual stop-and-restart plan must be personalised.

Is increased urination expected with Empagliflozin?

Increased urination can occur because the medicine causes glucose and additional water to leave through the kidneys. Mild changes may settle as the body adjusts, while severe thirst, dizziness, weakness, or fainting suggests excessive fluid loss. EMA product information from 2024 advises attention to volume depletion, especially in older adults and people taking diuretics.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Empagliflozin: Reviews and Experiences

3.9
Based on 4 reviews
Mariam, 58
Abu Dhabi
Several months
Verified
Rating: 4 out of 5

My glucose readings became steadier after the first few weeks. I urinated more in the morning, so taking the tablet later made sleep difficult. Drinking regularly helped, but I still needed follow-up for kidney results.

9 Oct 2026
Khalid, 64
Dubai
Several months
Verified
Rating: 4 out of 5

The medicine fitted my diabetes plan, and my weight decreased slightly. The first month brought light-headedness when standing. My clinician adjusted the fluid and blood-pressure plan, which made the symptom less troublesome.

19 Oct 2026
Aisha, 47
Sharjah
Several months
Verified
Rating: 4 out of 5

I did not feel an immediate difference. After a few months, my laboratory results improved. I developed genital itching once and treated it promptly; it was unpleasant but settled.

28 Oct 2026
Omar, 65
Al Ain
Early treatment period
Verified
Rating: 3.5 out of 5

The increased urination was more disruptive than expected, especially during a hot week. I stopped taking doses for a short time without advice, then needed a clearer sick-day plan. The follow-up conversation was useful.

5 Nov 2026

Sources

  1. U.S. Food and Drug Administration (2023). Jardiance (empagliflozin) Prescribing Information
  2. European Medicines Agency (2024). Jardiance: European Public Assessment Report
  3. American Diabetes Association (2024). Standards of Care in Diabetes—2024
  4. World Health Organization (2023). Diabetes: Fact Sheet
  5. National Institute for Health and Care Excellence (2022). Type 2 diabetes in adults: management
Get our free app Shop faster and track your orders 4.1 · 499 reviews Install